Your browser doesn't support javascript.
loading
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529.
Kharofa, Jordan R; Yothers, Greg; Kachnic, Lisa A; Ajani, Jaffer; Meyer, Joshua E; Augspurger, Mark E; Okawara, Gordon S; Garg, Madhur K; Schefter, Tracey E; Swanson, Todd A; Doncals, Desiree E; Kim, Hyun; Zaki, Bassem I; Narayan, Samir; Lee, R Jeffery; Mamon, Harvey J; Schwartz, Michael A; Moughan, Jennifer; Crane, Christopher H.
Afiliación
  • Kharofa JR; University of Cincinnati Cancer Center, Cincinnati.
  • Yothers G; NRG Oncology Statistics and Data Management Center.
  • Kachnic LA; Columbia University Medical Center.
  • Ajani J; M D Anderson Cancer Center, Houston.
  • Meyer JE; Fox Chase Cancer Center, Philadelphia, PA.
  • Augspurger ME; Baptist Medical Center South, Jacksonville, FL.
  • Okawara GS; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON.
  • Garg MK; Montefiore Medical Center-Moses Campus, Bronx NY.
  • Schefter TE; University of Colorado Denver, Aurora, CO.
  • Swanson TA; University of Texas Medical Branch, Galveston, TX.
  • Doncals DE; Summa Health System-Akron Campus, Akron, OH.
  • Kim H; Washington University School of Medicine, Saint Louis, MO.
  • Zaki BI; Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Narayan S; Saint Joseph Mercy Hospital, Ann Arbor, MI.
  • Lee RJ; Intermountain Medical Center, Murray, UT.
  • Mamon HJ; Brigham and Women's Hospital, Boston MA.
  • Schwartz MA; Mount Sinai Medical Center, New York, NY.
  • Moughan J; NRG Oncology Statistics and Data Management Center.
  • Crane CH; Memorial Sloan Kettering Cancer Center, New York, NY.
Am J Clin Oncol ; 45(12): 534-536, 2022 12 01.
Article en En | MEDLINE | ID: mdl-36413683
Novel toxicity metrics that account for all adverse event (AE) grades and the frequency of may enhance toxicity reporting in clinical trials. The Toxicity Index (TI) accounts for all AE grades and frequencies for categories of interest. We evaluate the feasibility of using the TI methodology in 2 prospective anal cancer trials and to evaluate whether more conformal radiation (using Intensity Modulated Radiation Therapy) results in improved toxicity as measured by the TI. Patients enrolled on NRG/RTOG 0529 or nonconformal RT enrolled on the 5-Fluorouracil/Mitomycin arm of NRG/RTOG 9811 were compared using the TI. Patients treated on NRG/RTOG 0529 had lower median TI compared with patients treated with nonconformal RT on NRG/RTOG 9811 for combined GI/GU/Heme/Derm events (3.935 vs 3.996, P=0.014). The TI methodology is a feasible method to assess all AEs of interest and may be useful as a composite metric for future efforts aimed at treatment de-escalation or escalation.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Ano / Radioterapia Conformacional / Radioterapia de Intensidad Modulada Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Am J Clin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Ano / Radioterapia Conformacional / Radioterapia de Intensidad Modulada Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Am J Clin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos